Introduction
15-Deoxy-D 12,14 -prostaglandin J 2 (15d-PGJ 2 ), an endogenous ligand of peroxisome proliferator-activated receptor c (PPARc), has potent antiproliferative properties in several types of cancerous or transformed cells as evidenced by its inhibition of malignant cell growth or induction of apoptosis (1, 2) . 15d-PGJ 2 induces apoptosis through modulation of genes associated with cell cycle and cell survival/death in various types of cancer cells. The antitumorigenic effects of 15d-PGJ 2 are also manifested by its inhibition of invasiveness and angiogenesis (3) . Moreover, 15d-PGJ 2 exerts anti-inflammatory effects that are associated with interruption of nuclear factor-jB and subsequent blockade of expression of some pro-inflammatory genes, such as cyclooxygenase-2 (COX-2) (reviewed in ref. 3) . However, there are some reports demonstrating the opposite effects of 15d-PGJ 2 on the development of tumors (1, 2) . Thus, 15d-PGJ 2 significantly enhanced the rate of formation, the size and vascularization of the papillomas when topically applied onto mouse skin (4) . 15d-PGJ 2 induced the proliferation of COX-2-depleted colorectal cancer (HCA-7) cells (5) .
However, precise mechanisms responsible for proliferative effects of 15d-PGJ 2 remain incompletely clarified.
It is noticeable that 15d-PGJ 2 is one of the major terminal products of COX-2. COX-2 has been shown to contribute to carcinogenesis by promoting cell proliferation and angiogenesis as well as by protecting cells from apoptosis (reviewed in ref. 6 ). Since abnormal overexpression of COX-2 is implicated in the pathogenesis of various human cancers, it is reasonable to assume that increased 15d-PGJ 2 synthesis as a consequence of COX-2 overexpression can facilitate carcinogenesis and tumor cell growth. Recently, Vichai et al. (7) reported the positive feedback regulation by 15d-PGJ 2 of COX-2 expression in mouse lung fibroblasts. Other studies also demonstrate the similar effect of 15d-PGJ 2 on COX-2 production (8) . However, molecular mechanisms by which 15d-PGJ 2 modulates COX-2 expression remain unresolved. In an attempt to elucidate the molecular mechanisms underlying 15d-PGJ 2 -mediated COX-2 upregulation, we explored the intracellular signaling pathways that can be possibly activated by this cyclopentenone prostaglandin in relation to its oncogenic potential in human breast cancer cells.
Materials and methods
Materials 15d-PGJ 2 , 9,10-dihydro-15d-PGJ 2 and GW9662 were purchased from Cayman Chemical Co. (Ann Arbor, MI). RPMI 1640 medium and fetal bovine serum were obtained from Gibco BRL (Grand Island, NY). Primary antibodies for Akt and pAkt were purchased from Cell Signaling Technology (Beverly, MA). Antibodies against COX-2 and actin were obtained from Lab Vision Corporation (Fremont, CA) and Sigma-Aldrich (St Louis, MO). LY294002, SB203580, SP600125 and U0126 were obtained from Tocris (Ellisville, MO). The antirabbit and anti-mouse horseradish peroxidase-conjugated secondary antibodies were purchased from Zymed Laboratories (San Francisco, CA). Oligonucleotide probes containing activator protein-1 (AP-1) consensus sequences located in the mouse COX-2 promoter region were obtained from Promega (Madison, WI). The enhanced chemiluminescence and [c- 32 P]ATP were supplied from Amersham Pharmacia Biotech (Buckinghamshire, UK).
Plasmid and expression vector
A series of human COX-2 promoter deletion constructs ligated to luciferase gene were described previously (9) . Hemaglutinin-tagged full-length Akt and Akt with a K179M mutation [kinase-dead (KD)-Akt] cloned into pCMV5 were kindly provided by Dr An-Sik Chung (Korea Advanced Institute of Science and Technology, Daejeon, South Korea) (10) . For analysis of AP-1, transcriptional activity and determination of the effects KD-Akt (Akt K179M ) on the expression of COX-2, MCF-7 cells were transfected with mammalian expression vectors. Appropriate control plasmids (pGL2 for COX-2 promoter deletion plasmids and AP-1-luciferase; hemaglutinin-tagged full-length Akt for KD-Akt) were used to properly assess the plasmid transfection effect.
Cell culture MCF-7 and MDA-MB-231 cells were maintained routinely in RPMI 1640 medium supplemented with 10% fetal bovine serum and 100 ng/ml penicillin-streptomycin-fungizone mixture at 37°C in a humidified atmosphere of 5% CO 2 /95% air.
MTT reduction assay. Cells were plated at a density of 3 Â 10 4 cells/300 ll in 48-well plates, and the cell viability was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) reduction assay. After incubation, cells were treated with the MTT solution (final concentration, 1 mg/ml) for 2 h. The dark blue formazan crystals formed in intact cells were dissolved with dimethyl sulfoxide and the absorbance at 570 nm was read using a microplate reader. Results were expressed as the percentage of MTT reduction obtained in the treated cells, assuming that the absorbance of control cells was 100%.
Abbreviations: AP-1, activator protein-1; COX-2, cyclooxygenase-2; CRE, cyclic AMP response element; 15d-PGJ 2 , 15-deoxy-D Thymidine incorporation. Cells were cultured in six-well dish and cotreated with [methyl-3 H]thymidine at a final concentration of 1 mCi/ml and dimethyl sulfoxide or 15d-PGJ 2 . After 24 h incubation, cells were trypsinized, washed with phosphate-buffered saline (PBS) and centrifuged. The supernatant was removed, and ice-cold 10% trichloroacetic acid solution (20 ml) was added to the pellet, followed by vortex mixing. The mixture was centrifuged, and the resulting pellet was mixed with 400 ml of 0.2 N NaOH (with 0.5% sodium dodecyl sulfate) and further incubated at 37°C for 30 min. After incubation, samples were mixed with 1 N HCl (68 ml) and 1 ml cocktail solution. Radioactivity in trichloroacetic acid-precipitable material was measured by liquid scintillation counting.
Western blot analysis MCF-7 cells (2 Â 10 5 cells/ml) were plated in a 60 mm dish and treated with 15d-PGJ 2 under specified conditions. After rinse with PBS, the cells were exposed to the lysis buffer [20 mM Tris-HCl (pH 7.5), 150 mM NaCl, 1 mM ethylenediaminetetraacetic acid disodium, 1 mM ethylene glycolbis(b-aminoethyl ether)-N,N,N#,N#-tetraacetic acid, 1% Triton, 2.5 mM sodium pyrophosphate, 1 mM beta-glycerophosphate, 1 mM Na 3 VO 4 , 1 lg/ml leupeptin and protease inhibitors] (Cell Signaling Technology) in the ice for 15 min. After centrifugation at 12,000g for 15 min, supernatant was separated and stored at À70°C until use. The protein concentration was determined by using the bicinchoninic acid protein assay kit (Pierce, Rockford, IL). Protein samples were electrophoresed on a 12% sodium dodecyl sulfate-polyacrylamide gel and transferred to polyvinylidene difluoride membrane at 300 mA for 3 h. Blots were incubated in fresh blocking buffer (0.1% Tween 20 in PBS containing 5% non-fat dry milk, pH 7.4) for 1 h followed by incubation with primary antibodies for COX-2, Akt, phospho-Akt/protein kinase B in PBS with 3% non-fat dry milk. After washing with 0.1% Tween 20 in PBS three times, blots were incubated with horseradish peroxidase-conjugated secondary antibody in PBS with 3% non-fat dry milk for 1 h at room temperature. Blots were washed again three times in 0.1% Tween 20 in PBS buffer, and transferred proteins were detected with an enhanced chemiluminescence detection kit (Amersham Pharmacia Biotech).
Preparation of nuclear proteins
After treatment with 15d-PGJ 2 , cells (3 Â 10 6 cells/10 ml in 100 mm dish) were washed with PBS, centrifuged and resuspended in ice-cold isotonic buffer A (10 mM 4-(2-hydroxyethyl)-1-piperazineethane sulfonic acid, pH 7.9, 1.5 mM MgCl 2 , 10 mM KCl, 0.5 mM dithiothreitol and 0.2 mM phenylmethanesulfonyl fluoride). After the incubation in ice bath for 10 min, cells were centrifuged again and resuspended in ice-cold buffer C containing 20 mM 4-(2-hydroxyethyl)-1-piperazineethane sulfonic acid (pH 7.9), 20% glycerol, 420 mM NaCl, 1.5 mM MgCl 2 , 0.2 mM EDTA, 0.5 mM dithiothreitol and 0.2 mM phenylmethanesulfonyl fluoride followed by incubation at 0°C for 20 min. After vortex mixing, the resulting suspension was centrifuged, and the supernatant was stored at À70°C after the determination of protein concentrations.
Electrophoretic mobility shift assay Briefly, the AP-1 oligonucleotide probe (5#-CGCTTGATGAGTCAGCCG-GAAC-3#) was labeled with [c- 32 P]ATP by T4 polynucleotide kinase and purified on a Nick column (Amersham Pharmacia Biotech). The binding reaction was carried out in a total volume of 25 ll containing 10 mM Tris-HCl (pH 7.5), 100 mM NaCl, 1 mM dithiothreitol, 1 mM EDTA, 4% glycerol, 0.1 mg/ml sonicated salmon sperm DNA, 10 lg of nuclear extracts and 100,000 c.p.m. of the labeled probe. A 100-fold excess of unlabeled oligonucleotide (competitor) was added where necessary. After 50 min incubation at room temperature, 2 ll of 0.1% bromophenol blue was added and samples were electrophoresed through a 6% non-denaturating polyacrylamide gel at 150 V for 2 h. Finally, the gel was dried and exposed to X-ray film.
Transient transfection and the luciferase reporter gene assay MCF-7 cells were plated at a confluence of 60% in six-well plate and grown in RPMI 1640 supplemented with 10% heat-inactivated fetal bovine serum at 37°C in a humidified atmosphere of 5% CO 2 /95% air. Transient transfections were performed using the N-[1-(2,3-dioleolloxy)propyl]-N,N,N-trimethylammonium methylsulfate (DOTAP) liposomal transfection reagents according to the instructions supplied by the manufacturer (Roche, Basel, Switzerland). After 8-12 h transfection, cells were treated with 15d-PGJ 2 for additional 12 h, and the cell lysis was carried out with the reporter lysis buffer. After mixing the cell extract with a luciferase substrate (Promega), the luciferase activity was measured by the luminometer (AntoLumat LB953, EG and G Berthold, Bad Widbad, Germany). The b-galactosidase assay was done according to the supplier's instructions (Promega b-Galactosidase Enzyme Assay System) for normalizing the luciferase activity.
Preparation of c-fos and c-jun antisense c-jun and c-fos antisense oligonucleotides were purchased from Bionics (Seoul, South Korea). The oligonucleotide sequences are as follows: c-jun, 5#-TGCAGTCATAGAAC-3#; c-fos, 5#-GAAGCCCGAGAACATCAT-3# and control, 5#-ATGAGTTTCTCGGGCTTG-3#. The cells were incubated with the c-jun and c-fos antisense oligonucleotides at different concentrations (1-10 lM) for 4 h followed by stimulation with 15d-PGJ 2 .
Measurement of intracellular reactive oxygen species accumulation
To monitor net intracellular accumulation of reactive oxygen species (ROS), the fluorescent probe 2#,7#-dichlorofluorescein diacetate was used. Following treatment, cells were rinsed with Krebs ringer solution and 10 lM 2#,7#-dichlorofluorescein diacetate was loaded. After 15 min incubation at 37°C, cells were examined under a confocal microscope equipped with an argon laser (488 nm, 200 mW).
Statistical analysis
When necessary, data were expressed as means ± SDs of at least three independent experiments, and statistical analysis for single comparison was performed using the Student's t-test. The criterion for statistical significance was P , 0.05.
Results
15d-PGJ 2 induces the expression of COX-2 in human breast cancer cells A kinetic study revealed that COX-2 protein expression was induced by 15d-PGJ 2 in a time-dependent manner ( Figure 1A ). Treatment with 15d-PGJ 2 (0, 3, 10 and 30 lM) for 24 h resulted in the induction of COX-2 in a concentration-dependent manner ( Figure 1B ). MCF-7 cells express estrogen receptor-a. We also examined the effect of 15d-PGJ 2 on COX-2 expression in an estrogen receptor-a-negative cell line, MDA-MB-231. As shown in Figure 1B , upregulation of COX-2 was observed in both cell lines. When both cells were treated with 30 lM 15d-PGJ 2 up to 24 h, $80% of treated cells were viable ( Figure 2 ). Although the prostaglandin exhibited some cytotoxicity at this time point, the COX-2 upregulation still continued ( Figure 1A ). Since 15d-PGJ 2 is known to provoke diverse effects by acting as an endogenous ligand of PPARc (11), we examined the effect of a PPARc antagonist GW9662 on COX-2 upregulation by 15d-PGJ 2 in MCF-7 cells. As illustrated in Figure 1C , 15d-PGJ 2 -induced COX-2 expression was not affected by GW9662 treatment. These findings indicate that COX-2 expression by 15d-PGJ 2 is independent of estrogen receptor and PPARc. 15d-PGJ 2 -induced COX-2 expression 15d-PGJ 2 upregulates the expression of COX-2 through AP-1 activation The regulation of COX-2 synthesis occurs mainly at the transcriptional level, although messenger RNA stabilization is also involved in response to specific signals. Transcription factors involved in the induction of COX-2 gene expression are diversified and cell type and/or stimulus specific. Several cis-acting elements are found in the COX-2 promoter, such as nuclear factor-jB, nuclear factor-interleukin-6, cyclic AMP response element (CRE) and E-box (12) (13) (14) . To determine which transcription factors are preferentially involved in 15d-PGJ 2 -induced COX-2 expression, cells were transfected with human COX-2 promoter-luciferase constructs (À327/þ59) ( Figure 3A ) and challenged with 15d-PGJ 2 for 12 h. Treatment with 15d-PGJ 2 resulted in a significant increase in the COX-2 promoter (À327/þ59) activity. To elucidate the critical region of the COX-2 promoter responsible for COX-2 expression by 15d-PGJ 2 , we utilized a series of COX-2 deletion constructs (À327/þ59, À220/þ59, À124/þ59 and À52/þ59). The COX-2 promoter activity was most prominent when the À327/þ59 promoter construct was used ( Figure 3B ). As the promoter length was shortened, COX-2 activities became gradually diminished. It is noticeable that the À52/þ59 construct exhibited an almost complete loss of the COX-2 promoter activity compared with the À327/þ59 construct. CRE is present between nucleotides À59 and À53, suggesting that this element might be responsible for mediating the COX-2-inducing effects of 15d-PGJ 2 . To precisely define which of these cis-acting elements are involved in 15d-PGJ 2 -induced COX-2 promoter activity, MCF-7 cells were transiently transfected with sitespecific mutant COX-2 promoter constructs. As shown in Figure   3C , CRM (À327/þ59 construct with mutation at the CRE site) significantly lowered the COX-2 promoter activity in 15d-PGJ 2 -treated cells. These results suggest that CRE plays an important role in mediating the induction of COX-2 gene expression by 15d-PGJ 2 in MCF-7 cells.
Based on these findings, we examined whether 15d-PGJ 2 could activate AP-1, a representative transcription factor that preferentially binds to CRE. The AP-1 proteins are homo-or heterodimers composed of basic region-leucine zipper proteins such as Jun, Fos and Jun dimerization partners and the closely related activating transcription factor subfamily proteins (ATF2, LRF1/ATF3 and B-ATF) (15, 16) . When MCF-7 cells were treated with 15d-PGJ 2 , the increased DNAbinding activity of AP-1 was observed up to 12 h ( Figure 4A ). Furthermore, 15d-PGJ 2 also enhanced the luciferase reporter activity of AP-1 ( Figure 4B ). To verify the role of AP-1 in regulating 15d-PGJ 2 -induced COX-2 expression, we designed antisense oligonucleotides for c-jun and c-fos that encode major AP-1 components as well as the control oligonucleotide containing the equal number of base pairs (17) . When cells were treated with each of the antisense oligonucleotides (1 or 10 lM) for 4 h prior to 15d-PGJ 2 treatment, both AP-1 DNA binding ( Figure 4C ) and COX-2 expression ( Figure 4D ) were reduced in a concentration-dependent fashion. The inhibitory effect of c-fos antisense on COX-2 expression as well as AP-1 DNA binding appeared to be stronger than that of c-jun antisense. These results (19) observed that c-fos antisense more effectively suppresses breast cancer cell growth than does c-jun antisense. From these studies, they (1 and 10 lM) . COX-2 protein levels were determined by Western blot analysis as described under Materials and Methods. Quantification of COX-2 immunoblot was normalized to that of actin followed by statistical analysis of relative image density.
Ã Significantly different from the value obtained with the dimethyl sulfoxide-treated group (P , 0.005).
ÃÃ Significantly different from the value obtained with the 15d-PGJ 2 -treated group (P , 0.005).
15d-PGJ 2 -induced COX-2 expression
conclude that c-Fos functions as a critical mediator of AP-1-regulated breast cancer cell growth. Our current results are consistent with those from these previous studies.
The expression of COX-2 is regulated via Akt activation
In an attempt to identify the upstream signaling pathways responsible for AP-1 activation and COX-2 induction by 15d-PGJ 2 , we initially examined its effect on the activation of mitogen-activated protein kinases (MAPKs), such as extracellular signal-regulated kinase, p38 and c-Jun N-terminal kinase, and also on the activation of the survival signaling represented by Akt. Akt is a serine/threonine kinase that regulates both growth and survival mechanisms by phosphorylating a large number of substrates (20) . Recent reports have shown that Akt regulates COX-2 overexpression in various cell cultures and in in vivo studies (21) (22) (23) . In line with this notion, 15d-PGJ 2 transiently activated Akt via phosphorylation ( Figure 5A ). In a subsequent experiment, MCF-7 cells were transfected with the plasmid carrying the KD-Akt with K179M mutation and then stimulated with 15d-PGJ 2 . MCF-7 cells transfected with functionally inactive Akt (KD) were much less responsive to 15d-PGJ 2 in terms of induced expression of COX-2 ( Figure 5B ) when compared with the cells transfected with wild-type Akt. To further verify the involvement of the phosphatidylinositol-3 kinase-Akt pathway in AP-1-mediated induction of COX-2 expression, cells were preincubated for 30 min with LY294002 (a phosphatidylinositol-3 kinase-Akt inhibitor) followed by treatment with 15d-PGJ 2 for additional 6 h. The pharmacologic inhibition of Akt with LY294002 abrogated 15d-PGJ 2 -induced COX-2 expression in a concentration-dependent manner ( Figure 5C ). Likewise, AP-1 DNA binding induced by 15d-PGJ 2 was attenuated by genetic and pharmacologic inhibition of phosphatidylinositol-3 kinase activity ( Figure 6 ). These findings suggest that 15d-PGJ 2 induces AP-1 activation and subsequently COX-2 expression via Akt activation. However, the pharmacologic inhibition of the other MAPKs (extracellular signal-regulated kinase, p38 and c-Jun N-terminal kinase) barely affected COX-2 induction by 15d-PGJ 2 ( Figure 5D ), suggesting that the MAPKs pathway are unlikely to be involved in 15d-PGJ 2 -induced COX-2 upregulation in MCF-7 cells.
15d-PGJ 2 generates ROS that induces COX-2 expression 15d-PGJ 2 and other cyclopentenone prostaglandins have been shown to induce the production of ROS in diverse cell types, which could mediate their effects on various cellular events (24) (25) (26) (27) . Therefore, we attempted to determine whether ROS could mediate the 15d-PGJ 2 -induced Akt activation and downstream signaling. Treatment of MCF-7 cells with 15d-PGJ 2 resulted in ROS production which was significantly suppressed by the addition of the ROS scavenger N-acetyl-L-cysteine (NAC) ( Figure 7A ). Pretreatment of MCF-7 cells with NAC significantly reduced 15d-PGJ 2 -induced phosphorylation of Akt ( Figure 7B ). Similarly, the increased DNA-binding activity of AP-1 caused by 15d-PGJ 2 was attenuated in the presence of NAC ( Figure 7C ). Furthermore, the 15d-PGJ 2 -induced COX-2 expression was also abolished by pretreatment with NAC ( Figure 7D ). These results suggest that ROS generated by 15d-PGJ 2 activate Akt and AP-1 signaling in sequence, which consequently induces expression of COX-2 in MCF-7 cells.
The a,b-unsaturated carbonyl moiety present in the cyclopentenone ring of 15d-PGJ 2 is crucial to induce ROS production and COX-2 expression The presence of the a,b-unsaturated carbonyl group in the cyclopentenone ring of 15d-PGJ 2 has been suggested to be prerequisite for inducing the alteration of cellular redox status and/or the modulation of target protein functions (3). This prompted us to determine whether the ROS production and activation of intracellular signaling for COX-2 induction by 15d-PGJ 2 is attributed to its characteristic a,b-unsaturated carbonyl functional group. To validate such structural requirement, MCF-7 cells were exposed to 15d-PGJ 2 and its analog 9,10-dihydro15d-PGJ 2 that lacks the cyclopentenone structure ( Figure 8A ), and induction of ROS production and COX-2 expression were compared. As shown in Figure 8B , while the intracellular ROS production in MCF-7 cells was induced by 15d-PGJ 2 , 9,10-dihydro-15d-PGJ 2 failed to induce ROS production. Moreover, 9,10-dihydro-15d-PGJ 2 was much less effective than 15d-PGJ 2 in inducing Akt activation and COX-2 expression ( Figure 8C ). Thus, elimination of the the a,bunsaturated carbonyl moiety by catalytic hydrogenation of the double bond in the cyclopentenone ring of 15d-PGJ 2 virtually abolished the pro-oxidant and pro-inflammatory effects of 15d-PGJ 2 , indicating that these biological activities can be attributed to the electrophilic carbon at the position 9 of 15d-PGJ 2 .
Discussion
Abnormally elevated COX-2 expression has been frequently, although not all, observed in human breast cancer tissues (28) (29) (30) (31) . In addition, COX-2 upregulation has been shown to correlate with distant metastases in breast cancer (32, 33) . Although some studies failed to find a significant correlation between aspirin use and breast cancer risk, there is now enough evidence for the involvement of COX-2 in breast cancer and for the beneficial effects of COX-2 inhibitors (34). While human breast tumor specimens exhibit elevated COX-2 levels, compared with surrounding tissues, there was relatively low extent of constitutive COX-2 expression in breast cancer cell lines that we examined. However, this is not surprising as augmented COX-2 expression as well as other pro-inflammatory enzymes/cytokines in human tumor tissues is influenced by the tumor microenvironment that is composed of surrounding host stromal tissue and infiltrated inflammatory/immune cells as well as tumors tissues. Such microenvironment is not anticipated to exist in cultured cells. However, when MCF-7 cells were treated with 15d-PGJ 2 in human breast cancer cell lines, COX-2 induction started as early as in 6 h and continued up to 24 h. 15d-PGJ 2 has been reported to inhibit AP-1 DNA-binding activity in interleukin-1b-treated mesangial cells (35) and human chondrocytes (36,37), which were PPARc dependent (37) or independent (35, 36) . Simonin et al. (38) demonstrated that 15d-PGJ 2 inhibited lipopolysaccharide-induced DNA-binding activity of AP-1 and nuclear factor-jB in a PPARc-independent manner. Jozkowicz et al. (39) reported that 15d-PGJ 2 inhibited AP-1 DNA-binding activity via PPARc-independent mechanisms in human umbilical vein endothelial cells. In particular, the antioxidant NAC blocked the inhibitory effect of 15d-PGJ 2 on AP-1 DNA binding, indicative of the involvement of ROS in 15d-PGJ 2 -mediated AP-1 inactivation (40) . The direct interaction of 15d-PGJ 2 with AP-1 proteins was revealed by PerezSala et al. (41) . However, our present study clearly demonstrates that COX-2 expression induced by 15d-PGJ 2 is mediated through DNA binding and transcriptional activity of AP-1, a representative transcription factor harboring the CRE-binding site. We found that a mutation at the CRE-binding site completely abolished the COX-2 promoter activity, suggesting that this site located in the COX-2 promoter plays a crucial role in regulating COX-2 transcription under the ROS are potent biological messenger molecules and have been implicated in the induction of gene expression through regulating several distinct intracellular signaling cascades (43) . A variety of cellular enzyme systems are potential sources of ROS production. These include NAD(P)H oxidase, xanthine oxidase, uncoupled endothelial NO synthase, arachidonic acid xenobiotic-metabolizing enzymes including cytochrome P-450, lipoxygenase, COX and enzymes in the mitochondrial respiratory chain (44) . ROS-induced oxidative stress is considered to be a general mechanism for AP-1 activation and COX-2 expression by a variety of agents (45, 46) . In support of this notion, the antioxidant NAC suppressed not only 15d-PGJ 2 -induced ROS production but also AP-1 DNA binding and COX-2 expression. Furthermore, NAC blocked the phosphorylation of Akt induced by 15d-PGJ 2 . These findings suggest that Akt can function as a downstream effector of ROS in transducing 15d-PGJ 2 -initiated signals via AP-1 to induce COX-2 expression in MCF-7 cells. However, the precise mechanism underlying association between ROS and Akt in 15d-PGJ 2 -induced signaling cascades remains to be clarified. One possibility for the activation of Akt is the interaction of 15d-PGJ 2 with phosphatase and tensin homologue deleted on chromosome 10 (PTEN), a negative regulator of the Akt pathway. A recent report has revealed that PTEN can be inactivated by formation of a disulfide bond between the active site Cys124 and Cys71 as a consequence of oxidation of these cysteine residues in NIH3T3 and HeLa cells treated with H 2 O 2 (47) . A preliminary data from our laboratory also revealed that 15d-PGJ 2 treatment inhibited the expression of PTEN in MCF-7 cells. Moreover, by utilizing biotinylated 15d-PGJ 2 , we were able to demonstrate the direct interaction of 15d-PGJ 2 with PTEN (E.-H.Kim and Y.-J.Surh, in preparation). Consequently, the inactivation of PTEN by 15d-PGJ 2 appears to contribute to the activation of Akt, leading to DNA binding of AP-1 and the expression of COX-2.
Several lines of evidence suggest ROS generation by exogenously added 15d-PGJ 2 . While molecular mechanisms of ROS generation by 15d-PGJ 2 remain to be defined, one plausible mechanism may involve conjugation of 15d-PGJ 2 with reduced glutathione (GSH), an important component of the cellular antioxidant defense system. Paumi et al. (48) demonstrated that 15d-PGJ 2 conjugated with GSH at carbon 9, whereas 9,10-dihydro-15d-PGJ 2 that lacks the electrophilic carbon center at position 9 failed to form such conjugate. It is well known that reduction of the cellular GSH results in the generation of ROS. In this regard, the formation of 15d-PGJ 2 -GSH conjugates may, at least in part, contribute to ROS production by this cyclopentenone prostaglandin. Another possibility of ROS production by 15d-PGJ 2 may involve disruption of mitochondrial respiratory electron flow. 15d-PGJ 2 increased ROS production in MCF-7 cells, which was attenuated by the mitochondrial complex I inhibitor rotenone (25) . Similar increases in ROS formation have also been reported in isolated mitochondria treated with 15d-PGJ 2 , and it is noteworthy that an electrophile-responsive proteome in the mitochondria is composed of proteins with reactive thiols (49-51). The cyclopentenone moiety of 15d-PGJ 2 has been proposed as a critical structural feature responsible for some of its biological effects (3). 9,10-Dihydro-15d-PGJ 2 , which differs from 15d-PGJ 2 only in the absence of the endocyclic double bond, was unable to generate ROS in MCF-7 cells, lending support that the electrophilic carbon center at position 9 of 15d-PGJ 2 is required for ROS formation. Consistent with this finding, 9,10-dihydro15d-PGJ 2 did not mimic the marked inducible effect of 15d-PGJ 2 on the expression of COX-2 as well as phosphorylation of Akt. Taken together, these observations suggest that the unique cyclopentenone structure of 15d-PGJ 2 is a critical determinant in its induction of COX-2 in MCF-7 cells.
Chronic inflammation is a well-known risk factor for cancer development. It is noteworthy that many malignant cells produce ROS to a greater extent than normal cells for their growth (43) . Just as inflammation can promote cancer development, a tumor often induces an inflammatory response that can be often mediated by ROS. In this context, 15d-PGJ 2 formed as a consequence of COX-2 induction may represent a potential molecular link between increased ROS production and chronic inflammation-induced cancer. Our present study does show that 15d-PGJ 2 functions as a positive regulator of COX-2 in human breast cancer cells via the Akt-AP-1 signaling pathway (Figure 9 ), which may provide these cells with survival advantage. As the expression level of COX-2 as well as the ability to respond to 15d-PGJ 2 is variable in different cell lines, our results obtained from a single cell line cannot be extrapolated to other cell lines. In order to explore the role of endogenous 15d-PGJ 2 in mammary carcinogenesis, our present study should be expanded to use of alternative cell lines and also tumor tissues, which have high expression level of COX-2. 
